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ABSTRACT: Benign Prostatic Hyperplasia (BPH) occurs in up to 
80% of men older than 70 years. The prevalence of BPH increases 
with age, from approximately 25% of men at 50 years of age to 50 
to 90% of individuals in their 8th decade of life. Treatment options 
for lower urinary tract symptoms (LUTS) secondary to BPH have 
been long restricted to drug therapy and, after failure of the former, 
surgical treatment. However, prostate surgery is associated with 
risks such as bleeding, necessity of transfusion and ejaculatory 
dysfunction. Several novel and minimally invasive methods for 
treatment of BPH have arisen in the past years. Common to all of 
these techniques are a more favorable safety profile and varying rates 
of success and clinical improvement, however frequently inferior to 
standard surgical techniques. Patients who will benefit the most from 
these procedures are those who would not wish to undergo surgery, 
those at prohibitively high risk for surgery, and those wishing to 
avoid ejaculatory dysfunction secondary to trans-urethral resection 
of the prostate (TURP) or open resection. Mechanical devices such 
as Temporary implantable nitinol device and Urolift appear to 
provide satisfying results with a favorable safety profile. Persistence 
of improvement is still questionable since follow-up longer than 5 
years is not available for these methods. Of note, these methods may 
be of limited performance for larger prostates, in special, Urolift for 
those with a large median lobe or a prostate larger than 100 grams. 
Similarly, novel techniques for tissue ablation, including convective 
water vapor energy, appear to offer promising and safe results, 
yet with limited follow-up. Prostate artery embolization (PAE) is 
another safe procedure and an option for patients who are not suited 
for surgery, with satisfying short and medium-term follow-up but 
unknown results at long-term. 
Keywords: Prostatic hyperplasia; Prostate; Minimally invasive 
surgical procedures.
RESUMO: A hiperplasia prostática benigna (HPB) ocorre em até 
80% dos homens acima de 70 anos. A prevalência da HPB aumenta 
com a idade, desde aproximadamente 25% dos homens com menos 
de 50 anos até 90% na oitava década de vida. Opções de tratamento 
para os sintomas de trato urinário inferior (STUI) secundários à 
HPB, por muito tempo, foram restritos a terapia medicamentosa 
e, na falência desta, tratamento cirúrgico. No entanto, as cirurgias 
prostáticas são associadas a riscos com sangramento, necessidade 
de transfusão, além da quase onipresente disfunção ejaculatória 
pós-operatória. Diversas técnicas novas e minimamente invasivas 
para tratamento da HPB surgiram nos últimos anos. Comum a todos 
esses métodos são um perfil de segurança favorável, porém com 
taxas de sucesso e de melhora clínica variáveis, mas frequentemente 
inferiores às encontradas nas técnicas cirúrgicas clássicas. Os 
pacientes que mais se beneficiam dessas técnicas novas são aqueles 
que não desejam passar por cirurgia; que possuem alto risco cirúrgico, 
além dos que desejam evitar a ejaculação retrógrada quase sempre 
presente após cirurgia aberta ou ressecção endoscópica da próstata. 
Dispositivos mecânicos como o TIND (Temporary implantable 
nitinol device, ou dispositivo temporário implantável de nitinol) e 
Urolift parecem oferecer resultados satisfatórios com um perfil de 
segurança amplamente favorável. A persistência da melhora dos 
sintomas é ainda questionável, uma vez que esses métodos ainda 
não contam com um seguimento superior a 5 anos. Também deve 
ser ressaltado que esses métodos podem ter sua performance limitada 
em próstatas excepcionalmente grandes. Em especial, o Urolift não 
deve ser indicado em pacientes com um lobo mediano proeminente 
ou com próstatas de peso estimado superior a 100 gramas. De forma 
semelhante, novas técnicas para ablação tecidual, como a ablação com 
energia convectiva de vapor de água, parecem oferecer resultados 
promissores e seguros, porém também com seguimento limitado. A 
embolização de artérias prostáticas é um outro procedimento seguro 
e uma opção para pacientes que não estejam aptos, pelo alto risco, a 
passar por cirurgias convencionais, com resultados de curto e médio 
prazo satisfatórios, porém também desconhecidos ao longo prazo. 
Descritores: Hiperplasia prostática; Próstata; Procedimentos 
cirúrgicos minimamente invasivos.
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INTRODUCTION
Benign Prostatic Hyperplasia (BPH), as a histological phenomenon, occurs in up to 
80% of men older than 70 years1. Prostatic growth may 
manifest as different lower urinary tract symptoms (LUTS), 
including storage and voiding symptoms. The prevalence 
of BPH increases with age, from approximately 25% of 
men at 50 years of age to 50 to 90% of individuals in their 
8th decade of life2,3. LUTS resulting from BPH may cause 
significant impairment in quality of life in older men, 
provoking at least mild modifications in lifestyle in up to 
80% of patients with BPH4. 
Treatment options for LUTS secondary to BPH have 
been long restricted to drug therapy or surgical treatment. 
Use of alpha adrenoceptor antagonists can be successful in 
reducing LUTS in short to mid term5,6, while inhibitors of 
the enzyme 5α-reductase may decrease long term risk of 
urinary retention7. When medical treatment fails, surgery is 
generally offered as the gold standard for treatment of BPH, 
including endoscopic resection with either laser or cautery 
energy, laparoscopic or open surgery. However, in recent 
years, several minimally invasive techniques for treatment 
of BPH have arisen, presenting promising functional with 
lesser risks for complications and a shorter hospital stay8. 
To date, there is evidence for short-term results for most 
of such techniques, although long-term results are still 
expected. In general, results appear to be slightly inferior 
in terms of urinary obstruction, with favorable outcomes 
in terms of morbidity and complications. Among these, 
Prostate Artery Embolization (PAE), mechanical devices 
and alternate sources for tissue resection are the main groups 
of techniques proposed. Interestingly, these techniques also 
avoid postoperative ejaculatory dysfunction, a complication 
that up to 77% of patients would like to avoid if given the 
chance9.
In this review, we will outline the most relevant 
minimally invasive options for treatment of BPH, the 
description of the techniques, the preliminary results, and 
limitations for each modality. 
Mechanical devices
Several mechanical devices, being permanent or 
temporary, have been developed in recent years, aiming to 
keep the patency of the prostatic urethra without need for 
hospitalization or invasive procedures. These models have 
been perfected, with resolution of issues such as rejection 
to foreign body, post-procedure pain and device migration8. 
Below, we will detail principles of each existing technique 
and current evidence for each method, respectively. 
Temporary implantable nitinol device (TIND)
This is a temporary device called Temporary 
implantable nitinol device (TIND, Medi-tate, Israel). 
It features a nitinol structure which is installed in the 
prostate through a transurethral approach with a 22 French 
cystoscope. The device is composed of an anchorage 
leaflet and radial structures which exert centrifugal force 
over the prostatic tissue to expand the prostatic urethra 
diameter (Figure 1). The installation of the device only 
requires light sedation and local anesthesia. This device is 
50 millimeters long and covers the whole extension of the 
prostate. Device withdrawn is usually programed within 5 
to 7 days from installation and is achieved with a bladder 
catheter, without need for hospitalization. The mechanism 
of action consists in induction of ischemia in the prostatic 
tissue, in the areas which are under pressure by the nitinol 
structure, hence remodeling the prostate and allowing for 
a larger urine flow through the urethra. 
Figure 1. Model representation of the position of the Temporary implantable nitinol device (TIND) in the prostate. Figure obtained 
from website of the manufacturer: http://www.medi-tate.com/patients/itind/
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A prospective study has evaluated the use of TIND 
in 32 patients with 1 year follow-up, assessing functional 
results, complications, feasibility and safety of use of 
this device10. Mean duration of the procedure was 5.8 
minutes, with same day discharge being adopted after initial 
experience with the first 20 cases. Short-term complications 
occurred in 12.5% of patients (urinary tract infection, 
prostatic abscess, acute urinary retention, transient urinary 
incontinence). However, there were no cases of late or 
persistent complications after 1 years; also of note, re-
interventions were not needed in any case to the end of 
follow-up. After 12 months, the authors noted a 67% raise 
of urinary flow rate and a 45% improvement in LUTS as 
evaluated with the International Prostate Symptom Score 
(IPSS). These authors concluded that the use of TIND 
is safe, easy, feasible and provides clinical efficacy in 
selected cases. There are currently 2 ongoing prospective 
studies further evaluating safety and performance of this 
device. TIND is not currently approved by the United 
States Food and Drug Administration, but it is approved 
for use in Brazil. 
Urolift
Urolift is a permanent device (Urolift, Neotract, 
United States of America) that creates a continuous path 
through the prostatic urethra, from the bladder neck to the 
verumontanum, by means of implants applied bilaterally 
to the prostatic lobes through the urethra, pushing the 
lobes laterally and thus permitting increased flow through 
the urethra (Figure 2)11. Each implant is composed of an 
urethral end made of stainless steel, a non-absorbable 
polyethylene monofilament and a capsular end made of 
nitinol. These implants are installed using a cystoscope; 
usually 2 or 3 pieces are required for each prostatic lobe. 
These implants compress and push the prostatic lobes 
laterally, so as to free the prostatic urethra. The application 
of implants requires only local anesthesia, without necessity 
for hospitalization. Furthermore, the present of the implants 
does not preclude later surgical interventions eventually 
needed for benign or malignant disease. However, the 
efficacy of the procedure is limited if the prostate weight 
exceeds 100 grams; also of note, results are deficient if there 
is a large median prostatic lobe. Urolift has been approved 
by the United States Food and Drug Administration; to date, 
it is not approved for use in Brazil. 
Urolift is the most studied minimally invasive 
mechanical device to date for the treatment of BPH. In a 
multicentric prospective randomized and controlled study 
including 206 patients, symptom improvement reached 50% 
as per IPSS evaluation; urinary flow rate increased by 64% 
3 months after the procedure12. Regarding the safety profile 
of the procedure, there were no complications or persistent 
side effects after 2 weeks from intervention; similarly, 
there was no impairment in sexual function as evaluated 
with the International Index of Erectile Function (IIEF). 
Patients from the same cohort, when re-evaluated after a 
5 year follow-up, had maintained the short-term benefits 
previously demonstrated13. Patients presented symptom 
improvement, as compared to baseline, of 44% as per 
IPSS evaluation; quality of life improvement of 42% and 
an increase in urinary flow rate of 41%. Other multicentric, 
prospective and randomized studies confirmed the effect 
of Urolift for the treatment of LUTS related to BPH, 
however less efficiently than Transurethral Resection of 
the Prostate (TURP)14,15. Notwithstanding, Urolift presented 
superior results in regard to post procedure recovery 
and sexual function, notably for not causing retrograde 
ejaculation. Such evidence have been corroborated by a 
recent meta-analysis including the currently existing data 
in the literature16.
Figure 2. Model representation of the application of the Urolift 
device through a cystoscope. The implants pull the prostatic tissue 
laterally and liberates the prostatic urethra from obstruction. 
Figure obtained from the website of the manufacturer: https://
www.urolift.com/
Tissue ablation
The process of prostatic tissue ablation by means of 
minimally invasive procedures has been tried in the past, 
for instance with transurethral ablation with radiofrequency 
and microwave treatment17. However, long-term follow-up 
of such techniques did not reveal persistent benefit of these 
procedures, with a frequent necessity for surgery months 
after primary intervention.
In recent years, the development of thermal tissue 
ablation with water steam, through the use of convective 
radiofrequency, has allowed for new possibilities. A new 
system for the treatment of BPH with prostate ablation, 
called Rezum, consists in the use of radiofrequency to 
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heat up water stored in the system turning it into steam; 
steam is then injected into the prostatic tissue and rapidly 
condensed, thus liberating thermal energy. This energy, in 
turn, leads to cell denaturation, tissue necrosis and vascular 
occlusion. This procedure is performed transurethrally 
with a cystoscope, requiring only local transrectal and 
urethral, with optional sedation. Steam applications are 
performed with a retractile needle through the cystoscope, 
with 1 centimeter of distance between injections (Figure 3). 
Patients are discharged on the same day of the procedure 
and should keep an indwelling bladder catheter for 1 week. 
Figure 3. Model representation of the Rezum system with transurethral application of water steam with a retractile needle through 
cystoscopy. Figure obtained from the website of the manufacturer: http://www.rezum.com/the-rezum-system/
Available studies to date have demonstrated that, 
after procedure, there is an increase in urinary flow rate 
of up to 6 milliliters per second, as well as a 11-point 
improvement of symptoms as evaluated with the IPSS18,19. 
So far, efficacy of the results has been demonstrated at the 
end of a 2-year follow-up19. Furthermore, prostate volume 
in patients undergoing Rezum ablation has decrease by 17 
to 28%18,20. Significantly, sexual function is well preserved 
after this procedure, with ejactulatory dysfucntion occuring 
in only 3% of subjects; erectile function impairment was 
noted only among patients with a previous dysfunction18,21. 
Among main complications, urinary tract infection 
occurred in 17% of patients and a transient urinary retention 
after catheter withdrawn happened in 14% of cases, while 
other complications such as urethral stenosis occurred in 
less than 4% of patients18. Efficacy of the procedure was 
not related to prostate volume. 
Prostatic Artery Embolization (PAE)
Prostatic Artery Embolization (PAE) was originally 
conceived as a treatment for refractory hematuria from 
prostatic etiology; however, it was later noticed that patients 
undergoing this therapy also improved in terms of LUTS. 
It subsequently started to be tested as a treatment for 
BPH among patients who were at high risk for a surgical 
procedure. PAE is performed by interventional radiologists 
through the femoral arteries with local anesthesia and 
allows for same day discharge. Major complications listed 
are transient ischemic proctitis, urethral burning, nausea 
and vomiting, with the short-term complications being 
identified as the “post-PAE syndrome”22. Also of note, is the 
risk of renal injury from contrast toxicity, as an angiography 
is needed in this procedure. 
Data available to date indicate that PAE presents 
high technical success rates and provides benefits in the 
treatment of LUTS secondary to BPH. Overall, symptom 
improvement and urinary flow rate increases are inferior to 
those of standard surgical treatment; however, for certain 
patients who are not suited for surgery due to a prohibitive 
risk, PAE can be a valuable option. In a prospective trial at 
University of Sao Paulo including 30 patients randomized 
to TURP or PAE, both procedures were considered efficient 
and safe; however, symptom improvement was higher for 
TURP but the complication profile was safer for PAE23. A 
retrospective study including 630 patients undergoing PAE 
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demonstrated clinical success at medium and long-term 
follow-up of 81% and 76%, with major complications 
in only 2 patients24. Yet, a recent meta-analysis of data 
available on PAE concluded that this technique should 
still be considered experimental, despite of safety evidence 
available25. Patients who are candidates for this procedure 
and not for surgery should be carefully selected and 
informed. 
CONCLUSIONS 
Several novel and minimally invasive methods for 
treatment of BPH have arisen in the past years. Common to 
all of these techniques are a more favorable safety profile 
and varying rates of success and clinical improvement, 
however frequently inferior to standard surgical techniques. 
Patients who will benefit the most from these procedures 
are those who would not wish to undergo surgery; those 
at prohibitively high risk for surgery and those wishing to 
avoid ejaculatory dysfunction secondary to TURP or open 
resection. Mechanical devices such as TIND and Urolift 
appear to provide satisfying results with a favorable safety 
profile. Persistence of improvement is still questionable 
since follow-up longer than 5 years is not available for 
these methods. Of note, these methods may be of limited 
performance for larger prostates, in special, Urolift for 
those with a large median lobe or a prostate larger than 
100 grams. Similarly, novel techniques for tissue ablation, 
including convective water vapor energy, appear to offer 
promising and safe results, yet with limited follow-up. 
Prostate artery embolization is another safe procedure and 
an option for patients who are not suited for surgery, with 
satisfying short and medium-term follow-up but unknown 
results at long-term. 
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